𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Scribed by Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Tabak; Meral Akdogan; Krzysztof Simon; Ulus S. Akarca; Robert Flisiak; Elke Verhey; Anneke J. Van Vuuren; Charles A. B. Boucher; Martijn J. ter Borg; Harry L. A. Janssen

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
189 KB
Volume
52
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

📜 SIMILAR VOLUMES

Prediction of the response to peg-interf
Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d

Prediction of sustained response to pegi
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic